


PHARMACEUTICAL 2019

OMEROS CORP Rank 280 of 363







PHARMACEUTICAL 2019

OMEROS CORP Rank 280 of 363



The relative strengths and weaknesses of OMEROS CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of OMEROS CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 26% points. The greatest weakness of OMEROS CORP is the variable Net Income, reducing the Economic Capital Ratio by 82% points.

The company's Economic Capital Ratio, given in the ranking table, is -39%, being 76% points below the market average of 37%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 89,867 |
| Cost of Goods Sold | 512 |
| Intangible Assets | 0 |
| Liabilities, Current | 37,356 |
| Liabilities, Non-Current | 0 |
| Other Assets | 2,224 |
| Other Compr. Net Income | 0 |
| Other Expenses | 3,323 |
| Other Liabilities | 0 |
| Other Net Income | -11,212 |
| Other Revenues | 29,868 |
| Property and Equipment | 3,845 |
| Research and Development | 89,860 |
| Selling, General and Administrative Expense | 51,718 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 95,936 |
| Liabilities | 37,356 |
| Expenses | 145,413 |
| Revenues | 29,868 |
| Stockholders Equity | 58,580 |
| Net Income | -126,757 |
| Comprehensive Net Income | -126,757 |
| Economic Capital Ratio | -39% |

